Triomics, an AI company focused on oncology, is partnering with Yale Cancer Center and Smilow Cancer Hospital in New Haven to improve access to clinical trials through artificial intelligence. The collaboration will apply Triomics’ AI-powered trial screening and feasibility technology to all active oncology trials within the Yale system, offering a significant advancement in how cancer research is conducted in Connecticut.

At institutions like Yale Cancer Center, where over 400 active trials are underway, manually reviewing patient charts—including handwritten notes, pathology records, and radiology reports—can be a barrier to efficient trial matching. Triomics’ platform scans unstructured data to generate a ranked shortlist of eligible trials for each patient, with transparent per-criterion explanations and source links.

Dr. Ian Krop, Professor of Medicine and Medical Director of the Yale Cancer Center Clinical Trials Office, said the new system will streamline the matching process: “As Connecticut's only National Cancer Institute-designated Comprehensive Cancer Center, and with more than 400 active clinical trials, we're always looking for ways to make clinical research more efficient and accessible to our patients. After a thorough evaluation, we are excited for the Triomics' platform to bring ease of access, structure, and transparency to the process, allowing our teams to focus more on enabling patients to enroll to appropriate trials and less on searching through charts.”

Yale Cancer Center Clinical Trials Office Executive Director Alyssa Gateman emphasized the operational impact, explaining, “By integrating the Triomics platform into our feasibility process, we can rapidly assess trial eligibility criteria using real-world patient data. This data-driven approach enhances our ability to anticipate enrollment challenges and ensure that new studies are positioned for success from the start.”

Triomics co-founder and CEO Sarim Khan noted the platform’s purpose is to assist—not replace—clinical expertise: “Our platform is designed to support, not replace, clinical judgment. It helps surface the right information more quickly and reliably. We're excited to work with the clinicians and research team at Yale Cancer Center to integrate our platform into their workflows and improve patient outcomes.”